Between Dec. 23, 2024 and Jan. 3, 2025, eCommons staff will not be available to answer email and will not be able to provide DOIs until after Jan. 6. If you need a DOI for a dataset during this period, consider Dryad or OpenICPSR. If you need support submitting material before the winter break, please contact us by Thursday, Dec. 19 at noon. Thank you!
Library

eCommons

 

Drug Delivery via GLIADEL Wafer for Treatment of Glioblastoma Multiforme (GBM)

Simple item page
dc.contributor.authorEricksen, William Leif
dc.contributor.authorFortin, Lyndsey
dc.contributor.authorHou, Cheryl
dc.contributor.authorShum, Katrina
dc.date.accessioned2008-07-23T19:53:42Z
dc.date.available2008-07-23T19:53:42Z
dc.date.issued2008-07-23T19:53:42Z
dc.description.abstractGlioblastoma multiforme (GBM), one of the most common primary glial tumors, is often treated with tumor resection surgery combined with GLIADEL wafers containing carmustine. These wafers are made with a degradable polymer that releases carmustine over a period of 5 days. Due to the localized nature of the release, no pharmacokinetic measurements have been taken in humans. In order to study the mass transfer of carmustine, COMSOL Multiphysics was used model the process and solve the transient convection-diffusion problem involved. A 2D axisymmetric geometry was used as a simplified schematic involving the wafer, tumor tissue, and normal tissue regions. Input parameters of diffusivity, reaction rates, and velocities were obtained from research involving carmustine drug delivery in human and monkey tissues. Results obtained showed a large initial increase of drug concentration within the first 12 hours localized within the tumor, followed by an exponential decrease during the remaining time period. This shows that the majority of cellular death was within the tumor. Results also indicated that elimination rate, velocity, and diffusivity were sensitive parameters. Furthermore, the model gave insight into what parameters can be changed in order to increase the concentration of carmustine in the tumor and decrease the concentration in the healthy tissue. Carmustine must be delivered to the tumor tissue at a certain concentration to be effective, so optimizing the parameters involved would create a better drug delivery system.en_US
dc.identifier.urihttps://hdl.handle.net/1813/11132
dc.language.isoen_USen_US
dc.relation.ispartofseriesBEE 453en_US
dc.subjectDrug deliveryen_US
dc.subjectGlioblastoma Multiformeen_US
dc.subjectcarmustineen_US
dc.titleDrug Delivery via GLIADEL Wafer for Treatment of Glioblastoma Multiforme (GBM)en_US
dc.typepresentationen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Group 5.pdf
Size:
500.94 KB
Format:
Adobe Portable Document Format
Download

Collections

BEE 4530 - 2008 Student Papers